Among 15 efficacy-evaluable patients with HER2-low expression breast cancer treated at the RP2D of 2.3 mg/kg, four (26.7%) patients experienced PR and five (33.3%) patients experienced SD. Here, ERBB2 is linked to breast carcinoma.